Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis
wherein A is chosen from
B is chosen from
wherein the variables R
1
to R
7
, m, n,
are as defined herein.
A method for treating the above diseases employing the above compounds is also provided.